한글목차

세계의 바이러스 벡터 및 플라스미드 DNA 시장 규모는 2024년에 6억 6,700만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 30.2%로 성장하여 2031년까지 41억 8,700만 달러에 이를 것으로 예측됩니다.

바이러스 벡터 및 플라스미드 DNA의 제조는 유전자치료, 세포치료, mRNA 백신, 차세대 바이오 의약품에 필수적인 업스트림 공정을 말합니다. 여기에는 고순도, 고발현 플라스미드 DNA의 생산과 아데노바이러스, 렌치바이러스, 아데노부수체바이러스(AAV) 등 고역가, 기능적으로 안정된 바이러스 벡터의 제조가 포함됩니다. 이러한 공정은 엄격한 GMP 조건 하에서 수행되며, 미생물 또는 포유류 발현 시스템을 사용하는 경우가 많으며, 발효, 정제, 품질 관리, 캡슐화 등의 주요 공정을 포함합니다. 바이오테크놀러지의 급속한 발전과 함께 이 분야는 실험실 규모의 생산에서 산업 규모의 제조로 진화하고 있으며, 전 세계 CDMO(위탁개발생산기관)와 바이오테크놀러지 기업의 전략적 초점이 되고 있습니다. 본 보고서에서는 연구용으로 사용되는 바이러스 벡터와 플라스미드 DNA만을 대상으로 합니다.

세포 및 유전자 치료의 상용화가 가속화되면서 바이러스 벡터와 플라스미드 DNA에 대한 세계 수요는 지속적으로 증가하고 있습니다. CAR-T 치료제, AAV 기반 유전자 치료제, mRNA 백신 프로그램 등 임상 및 상용화 단계에 진입하는 사례가 증가하고 있으며, 고품질 벡터 소재가 중요한 병목현상 자원으로 자리매김하고 있습니다. 한편, 유전자 치료 및 백신 생산의 현지화를 촉진하는 정부의 지원 정책은 GMP 준수 벡터 플랫폼에 대한 투자를 촉진하고 있습니다. CDMO 시장의 확대, 생명공학 기업의 아웃소싱 트렌드 강화, 생산 비용 절감을 위한 공정 최적화 노력과 함께 이 분야는 빠른 속도로 발전하고 있습니다.

수요는 견조한 반면, 기술적, 규제적 과제도 존재합니다. 표준화는 제한적이며, 플랫폼 간 생산의 일관성 확보는 여전히 어렵습니다. 품질 관리 수준이 높고, 바이러스 안전성, 잔류 핵산, 봉입 효율에 대한 엄격한 관리가 요구됩니다. 또한, 고품질 GMP 제조 능력은 여전히 소수의 다국적 기업에 집중되어 있으며, 신생 기업은 인프라 투자, 기술 전문성, 인력 확보에 어려움을 겪는 경우가 많습니다. 규제 당국의 감시도 강화되어 개발 기간이 길어지고 진입장벽이 높아지고 있습니다.

임상 파이프라인의 확대와 시판 제품 출시가 이 분야의 주요 촉진요인입니다. 희귀질환, 암 면역치료, 신경질환 등의 적응증에서 AAV 및 렌티바이러스 벡터의 사용이 눈에 띄게 증가하고 있습니다. 동시에, 플라스미드 DNA는 mRNA, 백신, 핵산 의약품, CRISPR 기반 치료법의 시작 템플릿 또는 전구체로 널리 사용되고 있습니다. 제약사와 CDMO 사업자 간의 전략적 제휴가 확대되고 있으며, 다양한 다운스트림 공정 용도를 지원할 수 있는 모듈식 및 확장 가능한 제조 플랫폼 개발이 진행되고 있습니다.

이 보고서는 바이러스 벡터 및 플라스미드 DNA 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목표로 합니다.

바이러스 벡터 및 플라스미드 DNA 시장 규모 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되었습니다. 정량적, 정성적 분석을 통해 독자들이 바이러스 벡터 및 플라스미드 DNA 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 포지셔닝 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

유형별 부문

• AAV
• 렌티바이러스
• 레트로바이러스
• 아데노바이러스
• DNA 플라스미드
• 기타

용도별 부문

• 제약회사 및 바이오의약품 기업
• 학술기관 및 연구기관

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동 및 아프리카

영문목차

The global market for Viral Vector and Plasmid DNA was estimated to be worth US$ 667 million in 2024 and is forecast to a readjusted size of US$ 4187 million by 2031 with a CAGR of 30.2% during the forecast period 2025-2031.

Viral Vector and Plasmid DNA Manufacturing refers to the upstream manufacturing processes essential for gene therapy, cell therapy, mRNA vaccines, and next-generation biologics. It includes the production of high-purity, high-expression plasmid DNA and the preparation of high-titer, functionally stable viral vectors such as adenovirus, lentivirus, and adeno-associated virus (AAV). These processes must be conducted under stringent GMP conditions, often using microbial or mammalian expression systems, and involve key steps such as fermentation, purification, quality control, and encapsulation. With the rapid advancement of biotechnology, this sector is evolving from lab-scale production to industrial-scale manufacturing, becoming a strategic focus for CDMOs and biotech firms worldwide.In this report, we only study the Viral Vector and Plasmid DNA used for research.

As the commercialization of cell and gene therapies accelerates, global demand for viral vectors and plasmid DNA continues to grow. An increasing number of CAR-T therapies, AAV-based gene therapies, and mRNA vaccine programs are advancing into clinical and commercial stages, positioning high-quality vector materials as critical bottleneck resources. Meanwhile, supportive government policies promoting the localization of gene therapy and vaccine production are driving investment in GMP-compliant vector platforms. The expanding CDMO market, stronger outsourcing trends among biotech companies, and process optimization efforts lowering production costs are jointly propelling this sector toward rapid development.

Despite strong demand, the sector faces technical and regulatory hurdles. Standardization remains limited, with cross-platform consistency in production still difficult to achieve. The bar for quality control is high, requiring strict management of viral safety, residual nucleic acids, and encapsulation efficiency. Moreover, premium GMP capacity is still dominated by a few multinational firms, while emerging players often face challenges in infrastructure investment, technical expertise, and talent acquisition. Regulatory scrutiny is also intensifying, lengthening development timelines and raising entry thresholds.

Clinical pipeline expansion and commercial product launches are the primary growth drivers for this field. In indications such as rare diseases, cancer immunotherapy, and neurological disorders, the use of AAV and lentiviral vectors is increasing significantly. At the same time, plasmid DNA is widely used as a starting template or precursor for mRNA, vaccines, nucleic acid drugs, and CRISPR-based therapies. Strategic partnerships between pharma and CDMO players are proliferating to develop modular, scalable manufacturing platforms that can support a diverse array of downstream applications.

This report aims to provide a comprehensive presentation of the global market for Viral Vector and Plasmid DNA, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vector and Plasmid DNA by region & country, by Type, and by Application.

The Viral Vector and Plasmid DNA market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector and Plasmid DNA.

Market Segmentation

By Company

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

Segment by Type

• AAV
• Lentiviruses
• Retroviruses
• Adenoviruses
• DNA Plasmids
• Other

Segment by Application

• Pharmaceutical and Biopharmaceutical Companies
• Academics and Research Institutes

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Viral Vector and Plasmid DNA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Viral Vector and Plasmid DNA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Viral Vector and Plasmid DNA in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Viral Vector and Plasmid DNA Product Introduction
• 1.2 Global Viral Vector and Plasmid DNA Market Size Forecast (2020-2031)
• 1.3 Viral Vector and Plasmid DNA Market Trends & Drivers
  • 1.3.1 Viral Vector and Plasmid DNA Industry Trends
  • 1.3.2 Viral Vector and Plasmid DNA Market Drivers & Opportunity
  • 1.3.3 Viral Vector and Plasmid DNA Market Challenges
  • 1.3.4 Viral Vector and Plasmid DNA Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Viral Vector and Plasmid DNA Players Revenue Ranking (2024)
• 2.2 Global Viral Vector and Plasmid DNA Revenue by Company (2020-2025)
• 2.3 Key Companies Viral Vector and Plasmid DNA Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Viral Vector and Plasmid DNA Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Viral Vector and Plasmid DNA
• 2.6 Viral Vector and Plasmid DNA Market Competitive Analysis
  • 2.6.1 Viral Vector and Plasmid DNA Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Viral Vector and Plasmid DNA Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector and Plasmid DNA as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 AAV
  • 3.1.2 Lentiviruses
  • 3.1.3 Retroviruses
  • 3.1.4 Adenoviruses
  • 3.1.5 DNA Plasmids
  • 3.1.6 Other
• 3.2 Global Viral Vector and Plasmid DNA Sales Value by Type
  • 3.2.1 Global Viral Vector and Plasmid DNA Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Viral Vector and Plasmid DNA Sales Value, by Type (2020-2031)
  • 3.2.3 Global Viral Vector and Plasmid DNA Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Pharmaceutical and Biopharmaceutical Companies
  • 4.1.2 Academics and Research Institutes
• 4.2 Global Viral Vector and Plasmid DNA Sales Value by Application
  • 4.2.1 Global Viral Vector and Plasmid DNA Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Viral Vector and Plasmid DNA Sales Value, by Application (2020-2031)
  • 4.2.3 Global Viral Vector and Plasmid DNA Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Viral Vector and Plasmid DNA Sales Value by Region
  • 5.1.1 Global Viral Vector and Plasmid DNA Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Viral Vector and Plasmid DNA Sales Value by Region (2020-2025)
  • 5.1.3 Global Viral Vector and Plasmid DNA Sales Value by Region (2026-2031)
  • 5.1.4 Global Viral Vector and Plasmid DNA Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.2.2 North America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.3.2 Europe Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Viral Vector and Plasmid DNA Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.5.2 South America Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Viral Vector and Plasmid DNA Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Viral Vector and Plasmid DNA Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Viral Vector and Plasmid DNA Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.3.2 United States Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.4.2 Europe Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.5.2 China Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.6.2 Japan Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.7.2 South Korea Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Viral Vector and Plasmid DNA Sales Value, 2020-2031
  • 6.9.2 India Viral Vector and Plasmid DNA Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Viral Vector and Plasmid DNA Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Thermo Fisher Scientific
  • 7.1.1 Thermo Fisher Scientific Profile
  • 7.1.2 Thermo Fisher Scientific Main Business
  • 7.1.3 Thermo Fisher Scientific Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.1.4 Thermo Fisher Scientific Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Thermo Fisher Scientific Recent Developments
• 7.2 Lonza
  • 7.2.1 Lonza Profile
  • 7.2.2 Lonza Main Business
  • 7.2.3 Lonza Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.2.4 Lonza Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Lonza Recent Developments
• 7.3 Azenta Life Sciences
  • 7.3.1 Azenta Life Sciences Profile
  • 7.3.2 Azenta Life Sciences Main Business
  • 7.3.3 Azenta Life Sciences Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.3.4 Azenta Life Sciences Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Azenta Life Sciences Recent Developments
• 7.4 Revvity
  • 7.4.1 Revvity Profile
  • 7.4.2 Revvity Main Business
  • 7.4.3 Revvity Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.4.4 Revvity Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Revvity Recent Developments
• 7.5 VectorBuilder
  • 7.5.1 VectorBuilder Profile
  • 7.5.2 VectorBuilder Main Business
  • 7.5.3 VectorBuilder Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.5.4 VectorBuilder Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.5.5 VectorBuilder Recent Developments
• 7.6 Takara Bio
  • 7.6.1 Takara Bio Profile
  • 7.6.2 Takara Bio Main Business
  • 7.6.3 Takara Bio Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.6.4 Takara Bio Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Takara Bio Recent Developments
• 7.7 GenScript Biotech
  • 7.7.1 GenScript Biotech Profile
  • 7.7.2 GenScript Biotech Main Business
  • 7.7.3 GenScript Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.7.4 GenScript Biotech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.7.5 GenScript Biotech Recent Developments
• 7.8 Gene Chem
  • 7.8.1 Gene Chem Profile
  • 7.8.2 Gene Chem Main Business
  • 7.8.3 Gene Chem Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.8.4 Gene Chem Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Gene Chem Recent Developments
• 7.9 Geno Meditech
  • 7.9.1 Geno Meditech Profile
  • 7.9.2 Geno Meditech Main Business
  • 7.9.3 Geno Meditech Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.9.4 Geno Meditech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Geno Meditech Recent Developments
• 7.10 PackGene Biotech
  • 7.10.1 PackGene Biotech Profile
  • 7.10.2 PackGene Biotech Main Business
  • 7.10.3 PackGene Biotech Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.10.4 PackGene Biotech Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.10.5 PackGene Biotech Recent Developments
• 7.11 VIROVEK
  • 7.11.1 VIROVEK Profile
  • 7.11.2 VIROVEK Main Business
  • 7.11.3 VIROVEK Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.11.4 VIROVEK Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.11.5 VIROVEK Recent Developments
• 7.12 OriGen
  • 7.12.1 OriGen Profile
  • 7.12.2 OriGen Main Business
  • 7.12.3 OriGen Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.12.4 OriGen Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.12.5 OriGen Recent Developments
• 7.13 Vector BioLabs
  • 7.13.1 Vector BioLabs Profile
  • 7.13.2 Vector BioLabs Main Business
  • 7.13.3 Vector BioLabs Viral Vector and Plasmid DNA Products, Services and Solutions
  • 7.13.4 Vector BioLabs Viral Vector and Plasmid DNA Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Vector BioLabs Recent Developments

8 Industry Chain Analysis

• 8.1 Viral Vector and Plasmid DNA Industrial Chain
• 8.2 Viral Vector and Plasmid DNA Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Viral Vector and Plasmid DNA Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Viral Vector and Plasmid DNA Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer